Newsfeeds Archive - Page 7 of 7

1 minute read

FDA
News

FDA Accepts For Priority Review Ascendis Pharma’s NDA For TransCon™ PTH In Adult Patients With Hypoparathyroidism

October 31, 8:02 AM

Ascendis Pharma A/S (NASDAQ:ASND) today announced that the U.S. Food & Drug Administration (FDA) has accepted for Priority Review its New Drug Application (NDA) for TransCon PTH (palopegteriparatide) in adult

ASND

1 minute read

Goldman Sachs Initiates Coverage On Ascendis Pharma with Buy Rating, Announces Price Target of $174

By Benzinga Newsdesk

October 20, 6:28 AM

Goldman Sachs analyst Paul Choi initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Buy rating and announces Price Target of $174.

ASND

1 minute read

Ascendis Seeks FDA Nod For TransCon PTH In Adults With Hypoparathyroidism

By Ragothaman Srinivasan

August 31, 11:48 AM

Ascendis Pharma (NASDAQ: ASND) has submitted a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for TransCon PTH, an investigational pro-drug designed to restore parathyroid hormone (PTH [1-34]) to physiological levels over 24 hours in adult patients with hypoparathyroidism.

ASND